ORPHA:252050
Primary melanoma of the central nervous system
Also known as: Malignant melanoma of meninges · Primary melanoma of the CNS
Publications
1,463
Trials
1
Interventional, condition-specific
Researchers
1,090
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
Primary melanoma of the central nervous system is a rare tumor of meninges arising from leptomeningeal melanocytes, typically in the perimedullary or high cervical region, in the absence of melanoma outside the CNS. The tumor is typically a darkly pigmented, solid mass, often containing hemorrhagic or necrotic areas, composed of sheets of pleomorphic cells with prominent nucleoli, with frequent mitotic figures and parenchymal invasion. Intracranial tumor may present with signs of raised intracranial pressure, focal neurological symptoms related to tumor location, or subarachnoid hemorrhage, spinal tumor may present with back pain, muscle weakness, numbness, plegia or urinary incontinence.
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0016747
- UMLS:C0349626
- NCIT:C5505
Additional Mondo synonyms (9)
CNS melanoma · Central nervous system melanoma · central nervous system melanoma · central nervous system melanoma (disease) · melanoma (disease) of central nervous system · melanoma of CNS · melanoma of central nervous system · melanoma of the CNS · melanoma of the Central nervous system
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
1,463 matched papers (919 in last 10 years) Source
- Phenotype characterisedNot found
No HPO disease–phenotype associations via Monarch for these Mondo IDs
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPresent
1 matched on ClinicalTrials.gov
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
None returned for this Mondo ID. That often means “not linked under this ID,” not “no clinical features.”
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
1,463
1,463 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
1,463 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
919 in the last 10 years · low confidence
Phrase hits: 1,463 · MeSH hits: 0
Who's working on it?
1,090
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Aziz N3 papers · 2026
Internal Medicine Department, Wyckoff Heights Medical Center, Brooklyn, New York, USA.
Papers in Europe PMC - 02Elsherif Y3 papers · 2026
Internal Medicine Department, Zayed Military Hospital, Abu Dhabi, UAE.
Papers in Europe PMC - 03
- 04
- 05Kinsler VA3 papers · 2024
Paediatric Dermatology, Great Ormond Street Hospital for Children NHS Foundation Trust, London, U.K.
Papers in Europe PMC - 06
- 07Tawbi H3 papers · 2023
Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Papers in Europe PMC - 08Wang Y3 papers · 2024
Department of Oncology, The Third People's Hospital of Zhengzhou, Zhengzhou, Henan 450000, China.
Papers in Europe PMC - 09Zhang Y3 papers · 2025
Department of Oncology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 201900, China.
Papers in Europe PMC - 10Abarzua-Araya Á2 papers · 2024
Dermatology Department, Hospital Clinic of Barcelona, University of Barcelona, 08036 Barcelona, Spain; (E.S.); (Á.A.-A.); (D.R.-P.); (J.M.); (S.P.); (S.P.)
Papers in Europe PMC
Clinical research
Is a treatment being tested?
1
interventional trials for this specific condition
1 interventional trial matched this specific condition name; none in our sample are currently recruiting. 2,889 trials are registered for melanoma, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 11 September 2026
1 interventional trial — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 80.1th percentile).
low confidence · 80.1th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
1 interventional trials matched after quoted-phrase search and title/condition post-filter.
No currently recruiting studies in the matched set. Open the same search on ClinicalTrials.gov.
Broader category: melanoma
2,889
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT07114172·NOT YET RECRUITING·Study of Melanoma-Resistant PET Monitoring Based on Key Rate-limiting Enzymes for Fatty Acid Metabolism in Healthy Volunteers
Not reviewed·Conditions: Melanoma (Skin Cancer) · Health Volunteers · PET / CT·Matched via name phrase
- NCT07070518·RECRUITING·Study of GV20-0251 in Participants With Solid Tumor Malignancies
Not reviewed·Conditions: Solid Tumor Cancer · Adult Refractory Cancer · Endometrial Carcinoma (EC) · Squamous Head and Neck Carcinoma·Matched via name phrase
- NCT05968690·RECRUITING·Naltrexone and Propranolol Combined With Immunotherapy
Not reviewed·Conditions: Advanced Melanoma·Matched via name phrase
- NCT06545682·RECRUITING·Phase Ib Study of AlpeliSib With PEmbroLizumab in Patients With mEtastatic Breast caNcer or melanomA (SELENA)
Not reviewed·Conditions: Melanoma (Skin Cancer) · Breast Cancer · Brain Metastasases·Matched via name phrase
- NCT05955924·RECRUITING·Nicotinamide Chemoprevention for Keratinocyte Carcinoma in Solid Organ Transplant Recipients - Pivotal Trial
Not reviewed·Conditions: Non-melanoma Skin Cancer · Carcinoma, Squamous Cell · Carcinoma, Basal Cell · Keratinocyte Carcinoma·Matched via name phrase
- NCT07459543·NOT YET RECRUITING·A Study To Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Untreated, Unresectable or Metastatic Melanoma Participants In India
Not reviewed·Conditions: Untreated Melanoma · Unresectable Melanoma · Metastatic Melanoma·Matched via name phrase
- NCT06066138·RECRUITING·A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
Not reviewed·Conditions: Locally Advanced Alveolar Soft Part Sarcoma · Metastatic Alveolar Soft Part Sarcoma · Locally Advanced Non Small Cell Lung Cancer · Metastatic Non Small Cell Lung Cancer·Matched via name phrase
- NCT04119024·RECRUITING·Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Not reviewed·Conditions: Metastatic Malignant Solid Neoplasm · Metastatic Melanoma · Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 · Pathologic Stage IV Cutaneous Melanoma AJCC v8·Matched via name phrase
- NCT06739226·RECRUITING·Combination Immunotherapy Targeting Melanoma
Not reviewed·Conditions: Melanoma·Matched via name phrase
- NCT06214156·RECRUITING·A Clinical Study of T3011 in Subjects With Advanced Melanoma
Not reviewed·Conditions: Advanced Melanoma·Matched via name phrase
- NCT04282044·RECRUITING·Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
Not reviewed·Conditions: Solid Tumor, Adult · Triple Negative Breast Cancer · Colorectal Cancer · Hepatocellular Carcinoma·Matched via name phrase
- NCT07581509·NOT YET RECRUITING·Pharmacokinetics, Safety, and Immunogenicity of Bmab1800 and Keytruda® as Adjuvant Monotherapy in Patients With Melanoma
Not reviewed·Conditions: Adult Patients With Stage IIB, IIC, and Stage III Melanoma Following Complete Resection (Adjuvant Settings)·Matched via name phrase
- NCT05704647·RECRUITING·Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases
Not reviewed·Conditions: Melanoma (Skin)·Matched via name phrase
- NCT07371663·RECRUITING·An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors
Not reviewed·Conditions: Solid Cancers · NSCLC (Advanced Non-small Cell Lung Cancer) · Gastric (Stomach) Cancer · Endometrial Cancer·Matched via name phrase
- NCT06708663·RECRUITING·HX009+ IN10018 With or Without Standard Chemotherapy for Advanced Solid Tumours
Not reviewed·Conditions: Biliary Tract Cancer · Melanoma·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 28 · after dedupe 28 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 28 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (28)
- isrctn·ISRCTN13633989·Not yet recruiting·A Phase I/IIa trial of NVG-222 in participants with solid tumours
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN17108793·Recruiting·A flexible initiative to test therapies for Alzheimer’s disease
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN24846895·Recruiting·A study to explore the effect of immunotherapy drug, tebentafusp, on patients with clear cell sarcoma (ultra-rare, aggressive type of soft tissue sarcoma that primarily affects young adults)
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN49320109·Recruiting·A CAR T trial for amyloid light chain amyloidosis (AL Amyloid)
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN17891825·Recruiting·A first-in-human, phase 1/2, multicenter, open-label, dose escalation, confirmation and expansion study to evaluate the safety, pharmacokinetics and antitumor activity of TH9619 in subjects with advanced solid tumors (ODIN)
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN12434145·Recruiting·A first in human study to investigate the safety and tolerability of CV6-168 in combination with anti-cancer treatments in patients with advanced cancer.
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN16573769·No longer recruiting·DOMENICA: Randomized phase III trial in MMR deficient endometrial cancer patients comparing chemotherapy alone versus dostarlimab in a first-line advanced/metastatic setting
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN11391038·No longer recruiting·Darovasertib is being used in comparison to crizotinib versus investigators' choice of treatment for negative (no specific marker) in this rare type of eye cancer which has been spread to other parts of the body, beyond the eye.
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN17575409·Recruiting·Pressurised IntraPeritoneal Aerosolised Chemotherapy (PIPAC) in the management of cancers of the bowel, ovary and stomach: a randomised controlled trial of efficacy in peritoneal metastases
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN78740398·Recruiting·The first-in-human trial of MDX-124 in patients with advanced cancer
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN73037722·Recruiting·LION: lifting immune checkpoints with NSAIDs
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN24189848·No longer recruiting·Study of DS-1062a with or without pembrolizumab in advanced or metastatic non-small cell lung cancer
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN90634455·Recruiting·A trial of zanubrutinib treatment of patients with relapsed and refractory primary central nervous system lymphoma
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN99462035·No longer recruiting·Noradrenaline treatment of apathy and impulsivity in participants with Progressive Supranuclear Palsy syndromes
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN36585784·Recruiting·ATNEC - Axillary management in T1-3N1M0 breast cancer patients with needle biopsy-proven nodal metastases at presentation after neoadjuvant chemotherapy
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN16004234·Stopped·A multi-arm non-comparative platform trial of new second-line treatments for metastatic pancreatic cancer patients based on a patient's individual biomarkers
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN84434175·No longer recruiting·Trial of ipilimumab immunotherapy in recently diagnosed glioblastoma brain tumours
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN15025004·No longer recruiting·A phase IIa study of rituximab and varlilumab in relapsed or refractory B-cell malignancies
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN10038996·No longer recruiting·Myeloma XII (ACCoRd trial)
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN43889760·Stopped·A study examining the effect of Cimzia on inflammation in the brain
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN36210045·No longer recruiting·Radioimmunotherapy with 90Y Ibritumumab Tiuxetan in B-cell CD20+ indolent non-Hodgkin Lymphoma
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN85705844·No longer recruiting·Treatment of Chinese patients with metastatic gastric cancer where resection is not possible
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN18543567·No longer recruiting·MINDACT (Microarray In Node-negative Disease may Avoid Chemotherapy): a prospective, randomised study comparing the 70-gene signature with the common clinical-pathological criteria in selecting patients for adjuvant chemotherapy in node-negative breast cancer
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN03334163·No longer recruiting·A phase II study of Sutent (SU11248) as second line treatment in pleural mesothelioma after first line treatment with a platinum and antimetabolite
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN81261306·No longer recruiting·A randomised trial evaluating the vascular endothelial growth factor inhibitor, bevacizumab (AVASTin®), as adjuvant therapy following resection of American Joint Committee on Cancer (AJCC) stage IIB (T4aN0M0), IIC (T4bN0M0) and III (TxN1-2M0) cutaneous Melanoma
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Primary melanoma of the central nervous system — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Primary melanoma of the central nervous system" OR "Primary melanoma of central nervous system" OR "Malignant melanoma of meninges" OR "Malignant melanoma of the meninges" OR "Primary melanoma of the CNS" OR "Primary melanoma of CNS" OR "CNS melanoma" OR "Central nervous system melanoma" OR "central nervous system melanoma (disease)" OR "melanoma (disease) of central nervous system" OR "melanoma (disease) of the central nervous system" OR "melanoma of CNS" OR "melanoma of the CNS" OR "melanoma of central nervous system" OR "melanoma of the central nervous system"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Primary melanoma of the central nervous system" OR "Primary melanoma of central nervous system" OR "Malignant melanoma of meninges" OR "Malignant melanoma of the meninges" OR "Primary melanoma of the CNS" OR "Primary melanoma of CNS" OR "CNS melanoma" OR "Central nervous system melanoma" OR "central nervous system melanoma (disease)" OR "melanoma (disease) of central nervous system" OR "melanoma (disease) of the central nervous system" OR "melanoma of CNS" OR "melanoma of the CNS" OR "melanoma of central nervous system" OR "melanoma of the central nervous system"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 1 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"melanoma"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
- Publication count (1463) is implausibly high for prevalence class "<1 / 1 000 000" — treat as possible over-matching, not a measure of research intensity
Ingested 2026-07-27T10:59:03.280Z
